|
|
Article: Fundamental Review for QLT Inc.
- Article from:
- M2 Presswire
- Article date:
- February 13, 2007
CopyrightCOPYRIGHT 2007 M2 Communications Ltd. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
M2 PRESSWIRE-13 February 2007-Biotech News: Fundamental Review for QLT Inc.(C)1994-2007 M2 COMMUNICATIONS LTD
RDATE:13022007
QLT's drugs respond to a light touch. The company develops pharmaceuticals that are activated when exposed to light. Visudyne, developed and marketed with Novartis Ophthalmics, fights a type of age-related macular degeneration (AMD), a leading cause of blindness. The drug is approved in more than 70 countries. The firm hopes to expand Visudyne's indications for other types of AMD. QLT also has products in development for the treatment of benign prostate enlargement, rosacea, acromegaly (a pituitary disorder), and malnutrition. In ...
Related newspaper, magazine, and journal articles:
|
|
Article: QLT intends to appeal U.S. Eligard injunction.
PR Newswire;
February 28, 2006 ;
700+ words
... ... manufacturing, selling and offering for sale QLT USA, Inc.'s Eligard(R) product ... injunction for seven days from today. QLT USA plans to file an immediate appeal ... Atrix Laboratories, Inc. (now "QLT USA, Inc.") and Sanofi-Synthelabo ...
|
|